Spotlight
Topic
Brand Insights
Subscribe
- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
The Weight-Loss Gold Rush: Legal and Regulatory Implications
Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses:
- Top legal and regulatory concerns for investors considering when financing companies developing or marketing GLP-1 drugs
- How the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs
- What needs to be done for GLP-1s to be covered
- Steps companies developing weight-loss medications should take to ensure responsible and ethical practice
- Advice for investors and financiers who are considering entering the weight-loss medication market
Recent Videos
Related Content
Beyond the Birthrate: The Societal Costs of Maternal Mortality
September 6th 2024Podcast
Head of Medical Affairs and Outcomes Research at Organon, Charlotte Owens, MD, FACOG, discusses the most critical changes needed to close the gaps in R&D for maternal health solutions and how feasible they are to make.
